Approach to the Patient with Pancreatic Disease¶
Chapter 358 | Part 10: Disorders of the Gastrointestinal System
KEY CLINICAL POINTS¶
- Acute pancreatitis incidence is ~33.7 per 100,000 person-years (95% CI 23.3–48.8), with ~1.16 deaths per 100,000 person-years.
- Chronic pancreatitis prevalence is ~9.6 per 100,000 adults (95% CI 7.9–11.8) with 0.09 attributable deaths per 100,000 person-years.
- Serum lipase >3× ULN is the most sensitive and specific test for acute pancreatitis, with elevated levels typically persisting 3–7 days.
- Fecal elastase measurement is the gold standard for diagnosing exocrine pancreatic insufficiency in chronic pancreatitis.
- Stepwise diagnostic algorithm for chronic pancreatitis includes contrast-enhanced CT, MRI/MRCP, EUS, and secretin-stimulated tests.
1. DEFINITION & OVERVIEW¶
Pancreatic disorders encompass acute and chronic pancreatitis, pancreatic cysts, and pancreatic cancer. Acute pancreatitis is a leading cause of hospitalization, with rising incidence. Chronic pancreatitis is irreversible, associated with poor quality of life, and a risk factor for pancreatic cancer. Pancreatic cysts are increasingly detected via imaging, with IPMN being the most common neoplasm. Pancreatic cancer is the seventh leading cause of cancer-related death in industrialized nations.
Table 358-1: Tests Useful in the Diagnosis of Acute and Chronic Pancreatitis and Pancreatic Neoplasms¶
| TEST | PRINCIPLE | COMMENT |
|---|---|---|
| Pancreatic Enzymes in Body Fluids | ||
| Serum lipase | Pancreatic inflammation leads to increased serum enzyme levels | Enzyme measurement of choice for acute pancreatitis; increased specificity if >3× ULN |
| Amylase | Simple; increased specificity if >3× ULN; may be falsely normal in hypertriglyceridemic pancreatitis | |
| Urine | Renal clearance of amylase increased in acute pancreatitis | Infrequently used |
| Ascitic fluid | Disruption of gland or main pancreatic duct leads to increased amylase concentration | Helps establish ascites source; false positives with intestinal obstruction/perforated ulcer |
| TEST | PRINCIPLE | COMMENT |
|---|---|---|
| Pleural fluid | Exudative pleural effusion with pancreatitis | False positives with lung carcinoma/esophageal perforation |
| Studies Pertaining to Pancreatic Structure | ||
| Radiologic and radionuclide tests | ||
| Plain film of abdomen | Demonstrates large calcifications in chronic pancreatitis | Infrequently used |
| Ultrasonography (US) | Limited info on edema, inflammation, calcification, pseudocysts, mass lesions | Noninvasive; useful for gallstone detection |
| Computed tomography (CT) | Detailed visualization of pancreas, surrounding structures, fluid collections, tumors | Preferred for staging pancreatic cancer; IV contrast needed |
| Magnetic resonance imaging (MRI) and MRCP | Noninvasive evaluation of pancreatic parenchyma, ducts, biliary system | More sensitive than CT for mild pancreatitis; no ionizing radiation |
| Endoscopic ultrasonography (EUS) | High-resolution imaging of pancreatic structure and function | Assesses gallstones, chronic pancreatitis, masses, cystic neoplasms; FNA/B for diagnosis |
| Endoscopic retrograde cholangiopancreatography (ERCP) | Therapeutic procedure for duct visualization | Invasive with iatrogenic risks |
| Tests of Exocrine Pancreatic Function | ||
| Secretin test | Secretin stimulates pancreatic juice and HCO3- secretion | Sensitive for occult disease; rarely performed |
| Endoscopic pancreatic function test (ePFT) | Secretin-stimulated collection during endoscopy | High negative predictive value for chronic pancreatitis; requires sedation |
| EUS-ePFT | Combines EUS evaluation with pancreatic juice collection | Single endoscopic assessment of structure/function |
| Secretin-stimulated MRCP | Imaging + semiquantitative pancreatic juice output | Noninvasive; less accurate than ePFT |
| Stool fat determination | Quantitative 72-h stool collection for fat malabsorption | Reliable reference standard; does not distinguish pancreatic vs. nonpancreatic causes |
| Fecal elastase | Pancreatic proteolytic enzyme not degraded in intestine | Diagnostic accuracy highest with pretest probability >100 mg/g; false positives with nonformed stools |
1.1 Global Epidemiology¶
Acute pancreatitis incidence: ~33.7 per 100,000 person-years (95% CI 23.3–48.8). Chronic pancreatitis prevalence: ~9.6 per 100,000 adults (95% CI 7.9–11.8). Pancreatic cancer mortality: 7th leading cause of cancer death in industrialized nations, 3rd most common in the US.
1.2 Diagnostic Challenges¶
Chronic pancreatitis diagnosis is hampered by nonspecific abdominal pain and limited access to direct pancreatic examination. Noninvasive tests (e.g., fecal elastase) are preferred over invasive methods for early detection.
2. EPIDEMIOLOGY¶
Acute pancreatitis incidence: ~33.7 per 100,000 person-years (95% CI 23.3–48.8). Chronic pancreatitis prevalence: ~9.6 per 100,000 adults (93% CI 7.9–11.8). Pancreatic cancer mortality: 7th leading cause of cancer-related death in industrialized nations, 3rd most common in the US. Pancreatic cysts: 2–5% detected on CT, 20–30% on MRI. IPMN is the most common neoplasm, with 0.04–5% prevalence at autopsy.
2.1 Risk Factors¶
Alcohol abuse, biliary tract disease, hypertriglyceridemia, medications (e.g., thiazides, estrogen), trauma, genetic mutations (e.g., PRSS1/R122H, SPINK1), and obesity.
2.2 Demographics¶
Acute pancreatitis: increasing incidence; chronic pancreatitis: decreasing admissions. Pancreatic cancer: higher in males, smokers, and those with diabetes or chronic pancreatitis.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Acute pancreatitis: biliary tract disease (40–60%), alcohol abuse (30–40%), medications, trauma, genetic factors. Chronic pancreatitis: long-term alcohol use, biliary obstruction, genetic mutations (e.g., CFTR, PRSS1, SPINK1), autoimmune factors. Pancreatic cysts: IPMN (precancerous), MCN (mucinous), serous cystadenoma (benign). Pancreatic cancer: multifactorial etiology including chronic inflammation, genetic predisposition, and oncogenic mutations (KRAS, p53).
3.1 Pathogenesis¶
Acute pancreatitis: activation of digestive enzymes within the pancreas, leading to autodigestion and inflammation. Chronic pancreatitis: progressive fibrosis, ductal obstruction, and exocrine/endocrine insufficiency. Pancreatic cancer: chronic inflammation, genetic mutations, and oncogenic pathways.
3.2 Genetic Factors¶
Hereditary pancreatitis (PRSS1/R122H, SPINK1 mutations), cystic fibrosis (CFTR mutations), and familial pancreatic cancer syndromes.
4. CLINICAL FEATURES¶
Acute pancreatitis: epigastric pain radiating to back, nausea/vomiting, fever, leukocytosis. Chronic pancreatitis: recurrent abdominal pain, steatorrhea, weight loss, diabetes mellitus. Pancreatic pseudocysts: abdominal distension, jaundice, or mass. Pancreatic cancer: jaundice, weight loss, obstructive symptoms. Pancreatic cysts: incidental findings; IPMN may present with obstructive jaundice or pancreatitis.
4.1 Acute vs. Chronic¶
Acute: sudden onset, severe pain, systemic inflammation. Chronic: progressive, recurrent pain, exocrine/endocrine insufficiency, diabetes.
4.2 Complications¶
Acute: necrosis, pseudocysts, sepsis. Chronic: diabetes, exocrine insufficiency, pancreatic cancer. Pancreatic cancer: metastasis, cachexia, obstructive jaundice.
5. DIFFERENTIAL DIAGNOSIS¶
Acute abdomen: cholecystitis, perforated peptic ulcer, intestinal obstruction. Chronic abdominal pain: peptic ulcer disease, irritable bowel syndrome, biliary disease. Pancreatic pseudocysts: ascites, splenic flexure syndrome. Pancreatic cancer: gallstones, lymphadenopathy, metastases. Hyperamylasemia: renal failure, salivary gland disease, macroamylasemia.
5.1 Nonpancreatic Causes¶
Renal insufficiency, salivary gland disease, macroamylasemia, burns, diabetes, pregnancy, and tumors (lung, breast, ovary).
6. INVESTIGATIONS & DIAGNOSIS¶
Serum lipase/amylase, fecal elastase, imaging (CT, MRI/MRCP, US, EUS). Diagnostic criteria for chronic pancreatitis: Cambridge class III, ≥ 5 EUS criteria, peak bicarbonate <80 mEq/L. Stepwise algorithm: CT → MRI/MRCP → EUS → secretin-stimulated tests.
Table 358-2: Causes of Hyperamylasemia¶
| Category | Causes |
|---|---|
| Pancreatic Disease | Acute/chronic pancreatitis, pseudocysts, necrosis |
| Pancreatic Trauma | |
| Pancreatic Adenocarcinoma | |
| Nonpancreatic Disorders | Renal insufficiency, salivary gland disease, tumors, macroamylasemia |
| Other Abdominal Disorders | Biliary disease, intraabdominal infections, postoperative hyperamylasemia |
6.1 Laboratory Tests¶
Serum lipase (>3× ULN), amylase, fecal elastase, stool fat analysis. Avoid amylase in renal failure; use lipase as primary test.
6.2 Imaging¶
CT (contrast-enhanced for necrosis), MRI/MRCP (noninvasive, no radiation), EUS (high-resolution, detects ductal abnormalities).
7. MANAGEMENT & TREATMENT¶
Acute pancreatitis: supportive care, NPO, IV fluids, analgesia. Chronic pancreatitis: abstinence from alcohol, pancreatic enzyme replacement, dietary modifications. Pancreatic pseudocysts: drainage (percutaneous/operative). Pancreatic cancer: surgery (Whipple), chemotherapy, radiation. Pancreatic cysts: surveillance (IPMN) or resection (MCN).
7.1 Acute Pancreatitis¶
NPO, IV fluids, analgesia, antibiotics for infected necrosis. Avoid NSAIDs; use opioids cautiously.
7.2 Chronic Pancreatitis¶
Enzyme replacement, dietary fat restriction, glucose control. Consider celiac plexus block for pain.
7.3 Surgical Interventions¶
Pseudocyst drainage, Whipple procedure for cancer, distal pancreatectomy for cysts.
8. PROGNOSIS & COMPLICATIONS¶
Acute pancreatitis: 1–2% mortality; severe cases (necrosis) have higher risk. Chronic pancreatitis: progressive disease, 10–20% mortality. Pancreatic cancer: 5-year survival <5%, with metastasis as primary cause of death. Complications include diabetes, exocrine insufficiency, and pancreatic cancer risk.
8.1 Acute vs. Chronic¶
Acute: variable prognosis; chronic: progressive decline with complications.
8.2 Long-term Risks¶
Chronic pancreatitis: 10–20% risk of pancreatic cancer; IPMN: 10–20% malignant potential.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: acute pancreatitis may be associated with fetal complications. Elderly: higher mortality, comorbidities. Pediatrics: congenital anomalies, hereditary pancreatitis. COVID-19: asymptomatic hyperlipasemia, increased risk of severe pancreatitis.
9.1 Pregnancy¶
Acute pancreatitis may be linked to fetal loss; avoid NSAIDs; monitor for preterm labor.
9.2 COVID-19¶
5.6% prevalence of hyperlipasemia; elevated amylase/lipase may indicate severe disease.
10. KEY POINTS & CLINICAL PEARLS¶
- Serum lipase >3× ULN is the best test for acute pancreatitis.
- Fecal elastase is the gold standard for exocrine insufficiency.
- Stepwise algorithm: CT → MRI/MRCP → EUS → secretin tests for chronic pancreatitis.
- IPMN requires surveillance; MCN may need resection.
- Avoid NSAIDs in acute pancreatitis; use opioids cautiously.
- Pancreatic cancer mortality is 7th leading cause of cancer death in industrialized nations.